De Wurstemberger B, Gysling E
Can Med Assoc J. 1976 Dec 4;115(11):1107-8.
Plasma renin activity (PRA) was studied before and during long-term treatment with moderate oral doses (0.2 or 0.3 mg/d) of clonidine. Nine outpatients with essential hypertension received clonidine for 12 weeks; a significant decrease in blood pressure was evident in all patients. Except for a nonsignificant increase after 12 weeks of treatment, PRA values were not notably changed by clonidine therapy. No correlation was found between individual blood pressure changes and PRA variation during the study. The absence of a net effect on PRA in this study does not exclude more complex interactions of clonidine with the renin-angiotensin system. Nonetheless, clonidine cannot generally be classified as a "renin-inhibiting" drug.
在长期口服中等剂量(0.2或0.3毫克/天)可乐定治疗之前和期间,对血浆肾素活性(PRA)进行了研究。9名原发性高血压门诊患者接受可乐定治疗12周;所有患者血压均显著下降。除治疗12周后有不显著升高外,可乐定治疗对PRA值无明显影响。研究期间,未发现个体血压变化与PRA变化之间存在相关性。本研究中可乐定对PRA无净效应,并不排除其与肾素-血管紧张素系统存在更复杂的相互作用。尽管如此,可乐定一般不能归类为“肾素抑制”药物。